Trial reportDigestive diseases and sciences2017
Controlled Attenuation Parameter (CAP) with the XL Probe of the Fibroscan
Trial report in Digestive diseases and sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed.
- Exposure-response modeling of liver fat imaging endpoints in non-alcoholic fatty liver disease populations administered ervogastat alone and co-administered with clesacostat.CPT: pharmacometrics & systems pharmacology · 2025Trial
- Heavy metals are liver fibrosis risk factors in people without traditional liver disease etiologies.Journal of environmental sciences (China) · 2025Article
- A prospective comparison of two ultrasound attenuation imaging modes using different frequencies for assessing hepatic steatosis.Ultrasonography (Seoul, Korea) · 2025Article
- The relationship between the ratio of non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol (NHHR) and both MASLD and advanced liver fibrosis: evidence from NHANES 2017-2020.Frontiers in nutrition · 2025Article
- Methods and Validation of Velacur Determined Fat Fraction in patients with MASLD.WFUMB ultrasound open · 2024Article
- External Validation of Serologic Scores for the Detection of Liver Steatosis Among People With HIV.Open forum infectious diseases · 2024Article
- Fibrosis and steatotic liver disease in US adolescents according to the new nomenclature.Journal of pediatric gastroenterology and nutrition · 2024Article
- Liver disease in patients with transfusion-dependent β-thalassemia: The emerging role of metabolism dysfunction-associated steatotic liver disease.World journal of hepatology · 2024Article
- Velacur ACE outperforms FibroScan CAP for diagnosis of MASLD.Hepatology communications · 2024Article
- Differences in liver and mortality outcomes of non-alcoholic fatty liver disease by race and ethnicity: A longitudinal real-world study.Clinical and molecular hepatology · 2023Article
- Modification of the diabetes prevention program for the treatment of nonalcoholic fatty liver disease: A pilot study.Obesity science & practice · 2023Article
- Pro-Inflammatory Adipokine and Cytokine Profiles in the Saliva of Obese Patients with Non-Alcoholic Fatty Liver Disease (NAFLD)-A Pilot Study.International journal of molecular sciences · 2023Article
- The Role of ElastPQ in Assessing Liver Stiffness for Non-Alcoholic Fatty Liver Disease in Patients Treated with Atypical Antipsychotic Drugs.Neuropsychiatric disease and treatment · 2023Article
- The association between non-alcoholic fatty liver disease (NAFLD) and advanced fibrosis with blood selenium level based on the NHANES 2017-2018.Annals of medicine · 2022Article
- Validation and Performance of FibroScan®-AST (FAST) Score on a Brazilian Population with Nonalcoholic Fatty Liver Disease.Digestive diseases and sciences · 2022Article
- Factors Associated With Liver Steatosis in People With Human Immunodeficiency Virus on Contemporary Antiretroviral Therapy.Open forum infectious diseases · 2022Article
- Accuracy of controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) for assessing steatosis and fibrosis in non-alcoholic fatty liver disease: A systematic review and meta-analysis.EClinicalMedicine · 2022Article
- Liver stiffness and liver function index in liver fibrosis patients afflicted with electrocardiographic abnormalities.Journal of family medicine and primary care · 2022Article
- Reproducibility of ultrasound-guided attenuation parameter (UGAP) to the noninvasive evaluation of hepatic steatosis.Scientific reports · 2022Article
- Non-invasive assessment of metabolic dysfunction-associated fatty liver disease.Therapeutic advances in endocrinology and metabolism · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionControlled attenuation parameter (CAP) is a new method for the diagnosis of steatosis. Until now, CAP was available only with the M probe of the Fibroscan. The aim of this study was to evaluate the diagnostic performance of CAP with the XL probe versus CAP with the M probe, using liver biopsy (LB) as gold standard. PATIENTS AND
methodsA total of 236 patients with chronic liver disease undergoing LB had CAP measurement with M and XL probes the same day. All LB were analyzed independently by two experienced pathologists.
resultsMedian CAP was 240.5 and 239.5 dB/m with the M and XL probes, respectively. For the detection of steatosis grade with the M and XL probes, AUROCs were 0.82/0.83 for S ≥ 1, 0.89/0.88 for S ≥ 2, and 0.92/0.93 for S3, respectively. Cutoffs were (M and XL probes) 246/242 for S ≥ 1, 269/267 for S ≥ 2, and 285/286 dB/m for S3, respectively. The factor significantly associated with CAP with the M and XL probes was steatosis grade. In multivariate analysis, a low CAP value with XL probe was negatively associated with waist circumference, triglycerides, albumin, and the alcohol consumption, and positively with alkaline phosphatases. In multivariate analysis, a high CAP value with the XL probe was positively associated with waist circumference and triglycerides.
conclusionCAP with the XL probe is a new tool for the diagnosis of steatosis. This parameter could be useful for the diagnosis and the follow-up of obese patients.
Indexed as
Identifiers
28577247What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.